MaxCyte, Inc. Notice of Results (7153O)
February 02 2023 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 7153O
MaxCyte, Inc.
02 February 2023
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial
Results on March 15, 2023 and Participate in Upcoming Investor
Conferences
ROCKVILLE, MD, February 2, 2023 - MaxCyte, Inc., (NASDAQ: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative cell-based research, today
announced that it will release financial results for the fourth
quarter and full year 2022 after the U.S. market close on
Wednesday, March 15(th) , 2023. Company management will host a
conference call to discuss financial results at 4:30 p.m. Eastern
Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are
required to register online. It is recommended to register at least
a day in advance. A live and archived webcast of the event will be
available on the "Events" section of the MaxCyte website at
https://investors.maxcyte.com/.
Company management will also participate in the following
investor conferences:
-- BIO CEO & Investor Conference
Tuesday, February 7(th) at 3:15 p.m. Eastern Time
-- BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Tuesday, February 14(th)
-- 43(rd) Annual Cowen Healthcare Conference
Tuesday, March 7(th) at 11:10 a.m. Eastern Time
A live and archived webcast of the Cowen presentation will be
available on the "Events" section of the MaxCyte investor relations
website at https://investors.maxcyte.com/ .
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation(R) platform, which facilitates
complex engineering of a wide variety of cells. Our ExPERT(TM)
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx(TM),
STx(TM) GTx(TM) and VLx(TM); a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property
portfolio.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORTTMFTMTIMMTJ
(END) Dow Jones Newswires
February 02, 2023 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024